Summary & Overview
CPT 86769: SARS–CoV–2 Antibody Multiple-Step Immunoassay
CPT code 86769 identifies a multiple-step immunoassay used to detect serum antibodies to SARS–CoV–2, the virus responsible for COVID‑19. As a serologic test, it plays a role in determining prior infection or immune response and is relevant for clinical interpretation, public health surveillance, and laboratory billing workflows nationwide. The code is used across hospital and independent clinical laboratories and factors into national laboratory testing patterns and payer coverage policies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context for serologic testing, the typical sites of service where the assay is performed, and the implications for billing and claims processing. The publication summarizes benchmark metrics, common modifier usage patterns, and payer coverage considerations where available. It also outlines regulatory and policy developments that affect lab-based SARS–CoV–2 antibody testing, and highlights operational considerations for laboratories submitting claims.
This summary is intended for a national audience of health policy analysts, billing professionals, and laboratory administrators seeking a clear overview of CPT code 86769, its clinical purpose, and the payer landscape relevant to serologic SARS–CoV–2 testing. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 86769 describes a laboratory multiple-step immunoassay performed to evaluate a patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), the virus that causes coronavirus disease 2019 (COVID–19). The service is a serologic antibody test that detects immune response rather than the virus itself.
Service type: Laboratory — serology/antibody assay
Typical site of service: Clinical laboratory or hospital laboratory
Associated procedural details, payers, modifiers, taxonomies, ICD-10 diagnoses, and related codes: Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult who presents for post‑infection or post‑vaccination assessment of immune response to SARS‑CoV‑2, or a patient with prior suspected COVID‑19 exposure who requires serologic testing. The clinical workflow begins when an ordering clinician (e.g., primary care physician, infectious disease specialist, occupational health provider) places an order for SARS‑CoV‑2 antibody testing. A phlebotomist collects a blood specimen (serum) in an outpatient clinic, hospital laboratory, or community testing site. The specimen is transported to the clinical laboratory where a medical laboratory scientist or lab analyst performs a multiple‑step immunoassay per 86769 to detect antibodies to SARS‑CoV‑2. Results are analyzed, reviewed by laboratory personnel, and reported to the ordering clinician via the electronic health record or laboratory information system. Typical sites of service include outpatient clinic laboratories, hospital inpatient/outpatient labs, reference laboratories, and public health laboratories. Common clinical reasons include evaluation of prior infection, assessment of humoral response after vaccination, or epidemiologic surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional component for test interpretation, if applicable |